Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944439 | 0.91 | MLYCD (0.83) | MLYCD | |
| SCHEMBL4431609 | 0.90 | MLYCD (0.82) | MLYCD | |
| SCHEMBL6843444 | 0.90 | MLYCD (0.81) | MLYCD | |
| SCHEMBL2938730 | 0.88 | MLYCD (0.82) | MLYCD | |
| SCHEMBL2938147 | 0.88 | MLYCD (1.00) | MLYCD | |
| SCHEMBL2944603 | 0.87 | MLYCD (0.98) | MLYCD | |
| SCHEMBL2941941 | 0.87 | MLYCD (0.98) | MLYCD | |
| SCHEMBL2940760 | 0.87 | MLYCD (1.00) | MLYCD | |
| SCHEMBL2935500 | 0.86 | MLYCD (1.00) | MLYCD | |
| SCHEMBL5230445 | 0.86 | MLYCD (0.96) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | IMBRIA PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250262310-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12318453-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | IMBRIA PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12318382-B2 | Methods of treating rheumatic diseases using trimetazidine-based compounds | IMBRIA PHARMACEUTICALS, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4531845-A1 | COMPOUNDS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4426301-A1 | METHODS FOR TREATING CARDIOVASCULAR CONDITIONS AND METHODS OF INCREASING THE EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240100173-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11844840-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | IMBRIA PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2020190671-A1 | METHODS OF TREATING CANCER USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200138963-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-20200138962-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2020-05-07 | — | — | US | disclosed |
| CN-111093662-A | Compositions and methods for improving cardiometabolic efficiency | 安布里亚制药公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3641769-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | Imbria Pharmaceuticals, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2020081361-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | IMBRIA PHARMACEUTICALS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-10556013-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | IMBRIA PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190216936-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018236745-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | CARNOT, LLC (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180360975-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | IMBRIA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318382-B2 | Methods of treating rheumatic diseases using trimetazidine-based compounds | TRIM4, HMGCR, FAH | MLYCD 2578/4885 |
| US-20250262310-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-10556013-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20260060978-A1 | METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS | TNNT2, TNNC1, CPT1B | MLYCD 1083/4885 |
| US-20180360975-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20240100173-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | MLYCD 6/4885 |
| US-20200138962-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-12318453-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20200138963-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-12569480-B2 | Methods of treating fibrosis using compounds that promote glucose oxidation | CPT1B, PFKP, PTK2 | MLYCD 656/4885 |
| US-11844840-B2 | Compositions and methods for increasing efficiency of cardiac metabolism | PC, PCK2, CPT1B | MLYCD 55/4885 |
| US-20190216936-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | PC, PCK2, CPT1B | MLYCD 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.